Covered recipient · General Payments record
JASON MATTHEW HAFRON
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$83,096.95
146 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $47,589.25 | 18 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,099.00 | 12 |
| Food and Beverage | $3,670.50 | 105 |
| Travel and Lodging | $2,670.20 | 10 |
| Education | $68.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JASON MATTHEW HAFRON
NPI 1255483277 · CMS profile ID 283707
Allopathic & Osteopathic Physicians / Urology
WEST BLOOMFIELD, MI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1255483277?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JASON MATTHEW HAFRON, NPI 1255483277, CMS profile ID 283707. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255483277?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JASON MATTHEW HAFRON, NPI 1255483277, CMS profile ID 283707. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255483277?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JASON MATTHEW HAFRON, NPI 1255483277, CMS profile ID 283707, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1255483277?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
146 matching records · $83,096.95 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 146.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,148.00 | 07/24/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207008427 | CMS |
| Merck Sharp & Dohme LLC | $34.60 | 07/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238271104 | CMS |
| Olympus America Inc. | $20.31 | 07/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223082012 | CMS |
| Ferring Pharmaceuticals Inc. | $58.42 | 07/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242068408 | CMS |
| AstraZeneca Pharmaceuticals LP | $116.61 | 07/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206612026 | CMS |
| Janssen Biotech, Inc. | $1,280.00 | 07/15/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174886129 | CMS |
| VERTEX PHARMACEUTICALS INCORPORATED | $17.95 | 07/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213950334 | CMS |
| Novartis Pharmaceuticals Corporation | $2,475.00 | 07/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200212869 | CMS |
| Novartis Pharmaceuticals Corporation | $13.69 | 07/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200334694 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $26.68 | 07/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225563667 | CMS |
| Novartis Pharmaceuticals Corporation | $15.73 | 06/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200334686 | CMS |
| Novartis Pharmaceuticals Corporation | $3.00 | 06/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200334688 | CMS |
| Sumitomo Pharma America, Inc. | $21.10 | 06/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176662725 | CMS |
| Janssen Biotech, Inc. | $15.29 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174885024 | CMS |
| PFIZER INC. | $22.28 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228906882 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.57 | 06/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206389730 | CMS |
| Novartis Pharmaceuticals Corporation | $4,950.00 | 06/16/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200212867 | CMS |
| Astellas Pharma Global Development | $2,100.00 | 06/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234126919 | CMS |
| Sumitomo Pharma America, Inc. | $3.07 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176662723 | CMS |
| Merck Sharp & Dohme LLC | $34.84 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238322658 | CMS |
| Novartis Pharmaceuticals Corporation | $0.53 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200334690 | CMS |
| Curium US LLC | $536.97 | 06/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235023649 | CMS |
| Curium US LLC | $228.46 | 06/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235023651 | CMS |
| Sumitomo Pharma America, Inc. | $24.29 | 06/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176662721 | CMS |
| Janssen Biotech, Inc. | $640.00 | 05/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174885204 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,296.00 | 05/27/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207303386 | CMS |
| AstraZeneca Pharmaceuticals LP | $83.16 | 05/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206380168 | CMS |
| AstraZeneca Pharmaceuticals LP | $741.65 | 05/21/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207295083 | CMS |
| Janssen Biotech, Inc. | $4,160.00 | 05/21/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174883796 | CMS |
| Janssen Global Services, LLC | $3,172.50 | 05/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1173805009 | CMS |
| PFIZER INC. | $1,500.00 | 05/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228839803 | CMS |
| PFIZER INC. | $1,000.00 | 05/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231616971 | CMS |
| Astellas Pharma US Inc | $23.51 | 05/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238790421 | CMS |
| Janssen Biotech, Inc. | $20.15 | 05/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174886038 | CMS |
| TOLMAR, INC. | $18.37 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237006932 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.90 | 05/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207035185 | CMS |
| AstraZeneca Pharmaceuticals LP | $1.20 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207050909 | CMS |
| Novartis Pharmaceuticals Corporation | $11.24 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200334684 | CMS |
| IMMUNITYBIO, INC. | $133.30 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233174852 | CMS |
| Sumitomo Pharma America, Inc. | $20.83 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176662719 | CMS |
| IMMUNITYBIO, INC. | $24.71 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233174814 | CMS |
| Olympus America Inc. | $26.16 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223082010 | CMS |
| ABBVIE INC. | $20.80 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201988649 | CMS |
| Astellas Pharma US Inc | $20.40 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238783453 | CMS |
| Laborie Medical Technologies Corp. | $15.60 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250406664 | CMS |
| Novartis Pharmaceuticals Corporation | $133.50 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200334668 | CMS |
| Dendreon Pharmaceuticals LLC | $22.09 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245001997 | CMS |
| PFIZER INC. | $17.33 | 04/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1231482207 | CMS |
| Novartis Pharmaceuticals Corporation | $13.68 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200334682 | CMS |
| Dendreon Pharmaceuticals LLC | $125.22 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1245001995 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $7,088.13 | 4 |
| PY2025 | Principal investigator | $1,962,351.80 | 110 |
| PY2024 | Principal investigator | $2,014,650.72 | 126 |
| PY2023 | Principal investigator | $2,215,528.56 | 112 |
| PY2022 | Principal investigator | $1,283,508.84 | 91 |
| PY2021 | Principal investigator | $995,280.34 | 100 |
| PY2020 | Principal investigator | $566,400.52 | 95 |
| PY2019 | Principal investigator | $356,842.38 | 147 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
114 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $37,491.28 | 12/31/2025 | Non-covered Recipient Entity Michigan Institute of Urology | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232927063 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,170.95 | 12/31/2025 | Non-covered Recipient Entity Michigan Institute of Urology | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232927065 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $358,623.65 | 12/29/2025 | Non-covered Recipient Entity Michigan Institute of Urology | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232927015 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,066.00 | 12/26/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361789 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $120.00 | 12/22/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176657682 |
| Principal investigator 1 | Janssen Research & Development, LLC | $554.00 | 12/15/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361811 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,437.00 | 12/15/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361931 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 12/10/2025 | Non-covered Recipient Entity Michigan Inst Of Uro PC | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175234326 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,033.00 | 12/01/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361774 |
| Principal investigator 1 | Janssen Research & Development, LLC | $456.00 | 11/24/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175234046 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,020.40 | 11/24/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361748 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,831.80 | 11/24/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361884 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,066.00 | 11/07/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361723 |
| Principal investigator 1 | Janssen Research & Development, LLC | $30,858.00 | 11/03/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361668 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,895.00 | 11/03/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361781 |
| Principal investigator 1 | PFIZER INC. | $4,042.00 | 11/01/2025 | Non-covered Recipient Entity Michigan Institute of Urology PC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228728503 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,442.40 | 10/27/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361714 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $21,212.55 | 10/15/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol | No dispute reported | 06/30/2026 | 1254646854 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,099.00 | 10/06/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361836 |
| Principal investigator 1 | Janssen Research & Development, LLC | $456.00 | 10/02/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175234074 |
| Principal investigator 1 | PFIZER INC. | $7,325.25 | 09/23/2025 | Non-covered Recipient Entity Michigan Institute of Urology PC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228770000 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $3,349.35 | 09/22/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol | No dispute reported | 06/30/2026 | 1254646852 |
| Principal investigator 1 | Janssen Research & Development, LLC | $610.60 | 09/19/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361767 |
| Principal investigator 1 | Janssen Research & Development, LLC | $270.00 | 09/19/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175361908 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,465.00 | 09/15/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361562 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 09/15/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361661 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,172.00 | 09/15/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361696 |
| Principal investigator 1 | Organon Llc | $32,623.01 | 09/10/2025 | Non-covered Recipient Entity Michigan Institute of Urology | 3475-676 | No dispute reported | 06/30/2026 | 1173042150 |
| Principal investigator 1 | Organon Llc | $11,770.38 | 09/10/2025 | Non-covered Recipient Entity Michigan Institute of Urology | 3475-676 | No dispute reported | 06/30/2026 | 1173042324 |
| Principal investigator 1 | Organon Llc | $12,570.38 | 09/10/2025 | Non-covered Recipient Entity Michigan Institute of Urology | 3475-676 | No dispute reported | 06/30/2026 | 1173042326 |
| Principal investigator 1 | Organon Llc | $1,901.00 | 09/10/2025 | Non-covered Recipient Entity Michigan Institute of Urology | 3475-676 | No dispute reported | 06/30/2026 | 1173042614 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,099.00 | 09/05/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361797 |
| Principal investigator 1 | Organon Llc | $200.00 | 09/03/2025 | Non-covered Recipient Entity Michigan Institute of Urology | 3475-676 | No dispute reported | 06/30/2026 | 1173042420 |
| Principal investigator 1 | Organon Llc | $135.00 | 09/03/2025 | Non-covered Recipient Entity Michigan Institute of Urology | 3475-676 | No dispute reported | 06/30/2026 | 1173042612 |
| Principal investigator 1 | Janssen Research & Development, LLC | $208.00 | 08/25/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361631 |
| Principal investigator 1 | Janssen Research & Development, LLC | $150.00 | 08/21/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361731 |
| Principal investigator 1 | PFIZER INC. | $9,667.55 | 08/09/2025 | Non-covered Recipient Entity Michigan Institute of Urology PC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228767221 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $7,000.00 | 08/08/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892332 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $556.25 | 08/08/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892335 |
| Principal investigator 1 | Janssen Research & Development, LLC | $85.00 | 08/04/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361653 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,007.00 | 07/25/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361570 |
| Principal investigator 1 | Janssen Research & Development, LLC | $240.00 | 07/25/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361675 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,521.00 | 07/25/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361818 |
| Principal investigator 1 | Janssen Research & Development, LLC | $610.60 | 07/24/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361862 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,600.00 | 07/17/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC | No dispute reported | 06/30/2026 | 1175361604 |
| Principal investigator 1 | Janssen Research & Development, LLC | $780.00 | 07/16/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175234082 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,132.00 | 07/07/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361690 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $20,096.10 | 07/01/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol | No dispute reported | 06/30/2026 | 1249804093 |
| Principal investigator 1 | Janssen Research & Development, LLC | $456.00 | 06/25/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175234060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,088.00 | 06/23/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361897 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $350.00 | 06/18/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176636389 |
| Principal investigator 1 | Janssen Research & Development, LLC | $384.00 | 06/16/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175234025 |
| Principal investigator 1 | Janssen Research & Development, LLC | $61.00 | 06/16/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361623 |
| Principal investigator 1 | PFIZER INC. | $8,792.75 | 06/13/2025 | Non-covered Recipient Entity Michigan Institute of Urology PC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228786231 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,066.00 | 06/09/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361762 |
| Recipient | Dendreon Pharmaceuticals LLC | $25.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891351 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,802.50 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891354 |
| Recipient | Dendreon Pharmaceuticals LLC | $2,550.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891359 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $50.00 | 06/05/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | ProvONE | No dispute reported | 06/30/2026 | 1247892173 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,802.50 | 06/05/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | ProvONE | No dispute reported | 06/30/2026 | 1247892181 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,550.00 | 06/05/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | ProvONE | No dispute reported | 06/30/2026 | 1247892185 |
| Recipient | Novartis Pharmaceuticals Corporation | $2,710.63 | 06/02/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190293444 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $12,280.95 | 05/28/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol | No dispute reported | 06/30/2026 | 1249804005 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,920.00 | 05/19/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175234040 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,877.00 | 05/19/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361755 |
| Principal investigator 1 | Janssen Research & Development, LLC | $180.00 | 05/19/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361917 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $946.31 | 05/19/2025 | Non-covered Recipient Entity Michigan Institute of Urology, PC | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with Pembrolizumab Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma KEYVIBE-010 | No dispute reported | 06/30/2026 | 1232936484 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,204.00 | 05/12/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361845 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,189.40 | 05/07/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634394 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $8,931.60 | 04/30/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol | No dispute reported | 06/30/2026 | 1249803932 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,033.00 | 04/28/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361938 |
| Principal investigator 1 | Janssen Research & Development, LLC | $610.60 | 04/28/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361960 |
| Principal investigator 1 | PFIZER INC. | $218.70 | 04/26/2025 | Non-covered Recipient Entity Michigan Institute of Urology PC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228780239 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,576.00 | 04/25/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361683 |
| Principal investigator 1 | PFIZER INC. | $874.80 | 04/15/2025 | Non-covered Recipient Entity Michigan Institute of Urology PC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228781103 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,421.00 | 04/11/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361868 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,104.40 | 04/11/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361968 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $10,048.05 | 04/09/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol | No dispute reported | 06/30/2026 | 1249803884 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,904.00 | 04/09/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632960 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,159.40 | 04/09/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632964 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,099.00 | 04/03/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361739 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $21,772.00 | 03/20/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) | No dispute reported | 06/30/2026 | 1242060279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $912.00 | 03/17/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175234098 |
| Principal investigator 1 | Janssen Research & Development, LLC | $270.00 | 03/17/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361829 |
| Principal investigator 1 | PFIZER INC. | $160.00 | 03/13/2025 | Non-covered Recipient Entity Michigan Institute of Urology PC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228798038 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,033.00 | 03/07/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361645 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.50 | 03/07/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361948 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $16,390.80 | 03/05/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol | No dispute reported | 06/30/2026 | 1249803700 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,500.00 | 03/05/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630282 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $533.26 | 03/03/2025 | Non-covered Recipient Entity Michigan Institute of Urology, PC | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232927017 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $2,150.00 | 02/26/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891755 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,550.00 | 02/26/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891759 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $11,164.50 | 02/26/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol | No dispute reported | 06/30/2026 | 1254646850 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,053.00 | 02/24/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361597 |
| Principal investigator 1 | Janssen Research & Development, LLC | $38.50 | 02/17/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361639 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,732.00 | 02/17/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361875 |
| Principal investigator 1 | Janssen Research & Development, LLC | $485.00 | 02/17/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361955 |
| Principal investigator 1 | Janssen Research & Development, LLC | $900.00 | 02/13/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175234068 |
| Principal investigator 1 | PFIZER INC. | $12,714.70 | 02/13/2025 | Non-covered Recipient Entity Michigan Institute of Urology PC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228769142 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,874.00 | 02/11/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175234033 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,516.00 | 02/10/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361613 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,831.80 | 02/03/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175361705 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $490,611.58 | 01/29/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185551587 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $15,630.30 | 01/29/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol | No dispute reported | 06/30/2026 | 1249803496 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $6,666.00 | 01/29/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176624976 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,134.00 | 01/20/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361580 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,034.00 | 01/20/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361586 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,291.00 | 01/20/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361802 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,291.00 | 01/20/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361854 |
| Principal investigator 1 | Janssen Research & Development, LLC | $75,974.00 | 01/20/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361890 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,670.00 | 01/20/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175361922 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,400.00 | 01/10/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175234053 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,860.00 | 01/10/2025 | Non-covered Recipient Entity Michigan Inst Of Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175234090 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $277,103.90 | 01/03/2025 | Non-covered Recipient Entity MICHIGAN INSTITUTE OF UROLOGY PC | a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco | No dispute reported | 06/30/2026 | 1185551589 |